The activation of SIRT1 shows potential against the physiological mechanisms related to NAFLD, and its plasma levels have been found to be increased in obese patients with NAFLD [50]. This evidence concerns the gene SIRT1 and metabolic dysfunction-associated steatotic liver disease.